A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.
Guangdong Association of Clinical Trials
Henan Cancer Hospital
Sungkyunkwan University
Second Affiliated Hospital of Nanchang University
Guangdong Association of Clinical Trials
Sun Yat-sen University
Guangdong Association of Clinical Trials
The First Affiliated Hospital of Soochow University
Shenzhen People's Hospital
Second Affiliated Hospital of Nanchang University
Fujian Cancer Hospital
Samsung Medical Center
Qilu Pharmaceutical Co., Ltd.
Jiangsu Famous Medical Technology Co., Ltd.
China Medical University, China
Peking University Cancer Hospital & Institute
Peking University Third Hospital
Shanghai Chest Hospital
Tongji University
SciClone Pharmaceuticals
First People's Hospital of Hangzhou
Qilu Hospital of Shandong University
Lady Davis Institute
Sun Yat-sen University
Shaanxi Provincial People's Hospital
Shanghai Chest Hospital
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National University Hospital, Singapore
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Asan Medical Center
Samsung Medical Center
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Peking Union Medical College Hospital
National Cancer Center, Korea
ZhuGuangYing
Fudan University
Zhejiang Cancer Hospital
Samsung Medical Center
National Cancer Institute (NCI)
Fudan University
GuangdongPPH